Thailand, Other Countries Can Expect Lag In Getting H1N1 Vaccine
This article was originally published in PharmAsia News
Thailand stands to be a month behind many other nations in having an H1N1 vaccine available, according to the nation's pharmaceutical group. Teera Chakajnarodom, president of the country's Pharmaceutical Research and Manufacturers Association, said the world's drug makers would likely produce only about 2.4 billion doses of a flu vaccine, far short of the planet's 7 billion population. Add in the planned concentration of distribution to areas most in need and Thailand could expect a vaccine available elsewhere in September no earlier than October. (Click here for more
You may also be interested in...
Gilead's remdesivir is first drug fully approved by FDA to treat COVID-19. Roche and Atea team up on an investigational direct acting antiviral while Moderna reaches the 30,000-patient enrollment target for its Phase III COVE study of the company's investigational mRNA vaccine.
From efficacy endpoints to patient warehousing, US FDA advisors weigh in on vaccine development and regulatory review.
Several years ago, heart device giant Edwards Lifesciences realized it needed a new CAPA framework that shifts corrective and preventive action from a one-size-fits-all method to a more nuanced approach. See what Dan Buehner, director of quality engineering at Edwards Lifesciences, said about it here.